Perspective Therapeutics initiated with a Buy at BofA

BofA analyst Alec Stranahan initiated coverage of Perspective Therapeutics with a Buy rating and $24 price target. The clinical-stage radiopharma company is developing cancer treatments through its unique use of radioactive Lead-212, or 212Pb, which offers higher potency and lower tissue penetration than traditional “beta emitting” particles, notes the analyst, who sees “a good cadence of clinical readouts” to come over the next six to 12 months.